
    
      The drug tested in this study was called ixazomib (MLN9708). Ixazomib was tested to treat the
      people with newly diagnosed multiple myeloma requiring systemic treatment who were not
      eligible for stem cell transplantation. This study determined the safety, tolerability,
      efficacy, quality of life (QOL), and pharmacokinetics (PK)/pharmacodynamics (PD) of ixazomib.

      The study enrolled 61 patients. The study was conducted in 2 parts: 1) phase 1 dose
      escalation and 2) phase 2 expansion at maximum tolerated dose. Participants were enrolled to
      receive:

        -  Ixazomib 3.0 mg, 3.7 mg, 4.0 mg, or 5.5. mg depending on the treatment assignment

      This multicenter trial was conducted in the Unites states, Canada, United Kingdom, Spain and
      Czech Republic. The overall time to participate in this study is 5.5 years. Participants made
      multiple visits to the clinic and were followed up every 16 weeks after end of treatment
      until disease progression if stopped treatment before disease progression and then every 16
      weeks up to start of next therapy or death whichever occurs first.
    
  